Tag Archives: her2-targeted therapy

Breakthrough Therapy Designation for Enhertu in HER2-Low Metastatic Breast Cancer

FDA grants Enhertu breakthrough therapy designation for HR+, HER2-low metastatic breast cancer. This offers new.....Read more